EP2984103B1 - Peptides and binding partners therefor - Google Patents
Peptides and binding partners therefor Download PDFInfo
- Publication number
- EP2984103B1 EP2984103B1 EP14722312.7A EP14722312A EP2984103B1 EP 2984103 B1 EP2984103 B1 EP 2984103B1 EP 14722312 A EP14722312 A EP 14722312A EP 2984103 B1 EP2984103 B1 EP 2984103B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- seq
- albicans
- ece1
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 165
- 230000027455 binding Effects 0.000 title claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title description 31
- 241000222122 Candida albicans Species 0.000 claims description 74
- 208000015181 infectious disease Diseases 0.000 claims description 39
- 230000009870 specific binding Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000006378 damage Effects 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 229940095731 candida albicans Drugs 0.000 claims description 14
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 241000144583 Candida dubliniensis Species 0.000 claims description 6
- 241000222178 Candida tropicalis Species 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 description 27
- 239000000523 sample Substances 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 102000001301 EGF receptor Human genes 0.000 description 15
- 108060006698 EGF receptor Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 11
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 9
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 201000003984 candidiasis Diseases 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010007134 Candida infections Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 5
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000012868 Overgrowth Diseases 0.000 description 5
- 230000003942 amyloidogenic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 206010042938 Systemic candida Diseases 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 210000002105 tongue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007027 Oral Candidiasis Diseases 0.000 description 3
- 101000606032 Pomacea maculata Perivitellin-2 31 kDa subunit Proteins 0.000 description 3
- 101000606027 Pomacea maculata Perivitellin-2 67 kDa subunit Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000013564 activation of immune response Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- -1 fluorescein isothiocyanates Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 101150113493 ECE1 gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150005709 ARG4 gene Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710083587 Antifungal protein Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017938 Gastrointestinal candidiasis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100030483 Histatin-1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101001082500 Homo sapiens Histatin-1 Proteins 0.000 description 1
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000007457 Oral Manifestations Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 1
- WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 1
- UBXIJOJXUFYNRG-MPJQEMCDSA-N PIP[5'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1C(O)[C@H](O)C(O)C(OP(O)(O)=O)C1O UBXIJOJXUFYNRG-MPJQEMCDSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 101100004044 Vigna radiata var. radiata AUX22B gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000019164 disseminated candidiasis Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005074 turgor pressure Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Definitions
- the present invention relates to moieties selected from a specific type of peptide and binding partners such as antibodies therefor, which have applications in diagnosis and therapy. Methods for using these moieties in diagnosis and therapy as well as in processes for screening for therapeutic compounds are also part of the invention.
- the isolated peptide and specific binding partners therefor are novel and form further aspects of the invention.
- Candida species are the most common fungal pathogens of humans and the causative agents of oral, gastrointestinal and vaginal candidiasis, giving rise to severe morbidity in millions of individuals worldwide. Vaginal candidiasis affects ⁇ 75% of women at least once during fertile age, equating to ⁇ 30 million infection episodes/year (3x more than tuberculosis and 8x more than HIV: WHO 2007).
- Candida infections are also the 3 rd most common hospital-acquired bloodstream infection, making Candida species more medically-important than most bacterial infections including Enterococci ( E. coli ) and Pseudomonas spp.
- Candida pathogens carry an immense health burden and represent a major socio-economic challenge for worldwide communities.
- Candida albicans is a member of the normal human microbiome. Although typically a commensal of the oral cavity, gastrointestinal and urinogenitary tracts, C. albicans is also an extremely frequent cause of superficial infections such as vaginitis. Moreover, common iatrogenic procedures, such as gastrointestinal surgery, implantation of a central venous catheter or antibiotic treatment are major risk factors for disseminated candidiasis. This form of systemic candidiasis is now the third most common cause of nosocomial bloodstream infections and the mortality of severe sepsis caused by Candida species is over 50% in some patient groups.
- C. albicans virulence relies on a number of factors, including morphological plasticity, the expression of adhesins and invasins, robust stress responses, immune evasion, metabolic flexibility and nutrient acquisition. However, it remains unclear, how C. albicans causes damage.
- C. albicans damages host cells have been considered to be multi-factorial, and presumed to rely on a combination of adhesion, invasion, hyphal extension, turgor pressure and the secretion of hydrolytic enzymes.
- toxin production by C. albicans has long been postulated and the culture supernatants of C. albicans hyphae shown to exhibit haemolytic activity, the mechanism underlying C. albicans ability to lyse host cells has remained elusive. It is clear, however, that hyphae are essential for adhesion, invasion and damage. Thus, damage is caused by hyphae and/or a hyphal associated factor.
- ECE1 e xtent of c ell e longation 1
- deletion of ECE1 did not affect hypha formation in C. albicans and phenotypic differences between C. albicans wild type and ECE1 deletion strains have not been reported.
- ECE1 expression has been used as a marker for hypha formation in multiple independent studies and ECE1 is one of the most strongly expressed genes during hyphal formation.
- ECE1 is within a small group of core hyphal associated genes. It has previously been reported that recombinant Ecel is processed by the protease, Kex2, at lysine/arginine residues. However, the function of Ecel has never been shown.
- Ecel plays a key role in host cell activation and damage, as demonstrated by the fact that deletion of ECE1 renders C. albicans unable to damage or activate inflammatory responses in human epithelial cells.
- a single peptide product of proteolytic processing of Ecel acts as a peptide toxin, in particular, a pore-forming toxin: the first such described in a human fungal pathogen.
- an optionally labelled peptide comprising SEQ ID NO 1
- S IIGIIMGIL GNIP QVIQIIMSIV KAFKGNKR SEQ ID NO. 1 or a variant thereof, or an immunogenic fragment of either of these; or a labelled form thereof.
- the expression 'variant' refers to a peptide sequence in which the amino acid sequence differs from the sequence of SEQ ID NO 1 in that one or more amino acids within the sequence are substituted for other amino acids.
- the variant produces a biological effect which is similar to that of SEQ ID NO 1.
- any variant will interact with the surface receptor EGFR (epidermal growth factor receptor) to give rise to activation of an immune response and/or immunoglobulins and in particular antibodies that are produced in response to said variants will cross-react with SEQ ID NO 1.
- the variant will be damage inducing in host cells, for example by acting as pore forming agents.
- Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid in the same class with broadly similar properties.
- Non-conservative substitutions are where amino acids are replaced with amino acids of a different type or class.
- Amino acid classes are defined as follows: Class Amino acid examples Nonpolar: A, V, L, I, P, M, F, W Uncharged polar: G, S, T, C, Y, N, Q Acidic: D, E Basic: K, R, H.
- altering the primary structure of a peptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This is so even when the substitution is in a region which is critical in determining the peptide's conformation.
- Non-conservative substitutions may also be possible provided that these do not interrupt the function of the peptide and in particular its ability to cross-react with immunoglobulins that react with SEQ ID NO 1.
- Particular variants may include peptides encoded by orthologues or paralogues of the gene sequence that encodes the peptide of SEQ ID NO 1 in C. albicans.
- Particular variant sequences are orthologues from C. dubliniensis and C. tropicalis as shown in Figure 2 hereinafter.
- variants will have amino acid sequences that will be at least 70%, for instance at least 71%, 75%, 79%, 81%, 84%, 87%, 90%, 93% or 96% identical to SEQ ID NO 1.
- Identity in this context may be determined using the BLASTP computer program with SEQ ID NO 1 as the base sequence.
- the BLAST software is publicly available at http://blast.ncbi.nlm.nih.gov/Blast.cgi (accessible on 12 March 2009).
- Variants may also include addition sequences such as tag sequences that may be used for instance in facilitating purification of the peptide or in detection of it.
- the variant may further comprise an affinity tag such as chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), FLAG, myc, biotin or a poly(His) tag as are known in the art.
- CBP chitin binding protein
- MBP maltose binding protein
- GST glutathione-S-transferase
- FLAG FLAG
- myc myc
- biotin biotin
- poly(His) tag as are known in the art.
- the variant may comprise a fluorescent protein such as green fluorescent protein (GFP).
- a chemical label such as a fluorescent or radio label.
- fluorescent or radio label there are a wide range of such labels available commercially, but examples include fluorescein and derivatives such as fluorescein isothiocyanates (FITC), carboxyfluorescein succinimidyl esters, fluorescein dichlorotriazine (DTAF) and 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE), rhodamine and derivatives such as carboxytetramethylrhodamine (TAMRA), tetramethylrhodamine (TMR) and its isothiocyanate derivative (TRITC), sulforhodamine, Texas Red, Rhodamine Red and the dyes available under the trade name Alexa.
- fluorescein and derivatives such as fluorescein isothiocyanates (FITC), carboxyfluorescein succinimidyl esters, fluorescein dichlorotriazine (
- fragment refers to any portion of the amino acid sequence of SEQ ID NO 1 which has biological function in common with SEQ ID NO 1. (e.g. damage-inducing, immunomodulatory or is immunogenic, for instance an epitopic fragment) and which reacts with specific binding partners for SEQ ID NO 1.
- Suitable fragments will include deletion mutants comprising up to 31 amino acids, for example at least 7 amino acids, such as at least 10, for instance at least 15, such as at least 20, more suitably at least 30 amino acids.
- Seq ID NO 1 includes two segments that contain sequences with high amyloidogenic potential (underlined), which may be involved in cell interactions and activation due to their hydrophobic nature and ability to potentially form ⁇ -helices.
- Particular variants or fragments of SEQ ID NO 1 will contain at least one of said sequences which are represented below as SEQ ID NO 2 and SEQ ID NO 3 respectively.
- IIGIIMGIL SEQ ID NO. 2
- QVIQIIMSIV SEQ ID NO. 3
- the peptide is a peptide of SEQ ID NO. 1.
- the peptide is in isolated or purified form and in particular is free of at least some and preferably all other peptides obtainable by Kex2 protease cleavage of the Ecel protein of C. albicans.
- the peptide may be isolated from C. albicans that has been subject to Kex2 protease digestion, in a particular embodiment, the peptide is prepared synthetically using conventional preparation methods.
- peptides of the invention and in particular the peptide of SEQ ID NO 1 has been found to be immunogenic.
- a specific binding partner for a peptide as described above; or a labelled form thereof are immunoglobulins, such as an antibody or a binding fragment thereof.
- suitable binding fragments of antibodies include Fab, Fab', F(ab)2, F(ab')2 and FV, VH and VK fragments.
- Antibodies may be polyclonal or monoclonal but in a particular embodiment, the antibodies are monoclonal antibodies.
- Antibodies can be prepared using conventional methods involving inoculation of an animal such as mouse or guinea pig with a peptide of the first aspect of the invention and harvesting antibodies from the blood thereof. Monoclonal antibodies can be obtained therefrom by fusing antibody producing cells such as spleen cells from the inoculated animal with a hybridoma cell, culturing this cell and harvesting monoclonal antibodies therefrom.
- the antibody may be chemically labelled to facilitate detection. Suitable labels will be similar to those described above for the peptides of the invention.
- the antibody may be detectable using a secondary antibody which is modified so as to be detectable using a development reaction, for example because it includes an enzymatic label, as is conventional in the art.
- a third aspect of the invention provides a peptide as described above for use in therapy, and in particular for the treatment or prevention of infection by Candida albicans.
- the therapy is for the treatment or prevention of oral, gastrointestinal or mucosal and in particular vaginal infection by Candida albicans.
- a non-toxic amount of a peptide as described above or a pharmaceutically acceptable composition comprising it is administered to a subject, such as a human or animal.
- the non-toxic amount is sufficient to produce an immune response that is protective against C. albicans infection.
- the peptide may be used as a vaccine in a vaccination method.
- Such a method forms a fourth aspect of the invention.
- the amount of peptide administered will vary depending upon factors such as the size and health of the patient, the nature of the condition being treated etc. in accordance with normal clinical practice. Typically, a dosage in the range of from 1 ⁇ g-50mg/Kg such as from 1-50 ⁇ g/Kg but in particular from 1-50mg/Kg, for instance from 2-20 mg/Kg, such as from 5-15 mg/Kg would be expected to produce a suitable immune response. Since the peptide of SEQ ID NO 1 has been found to have cytotoxic effects however, care must be taken to ensure that the dosage is sufficient to prime the immune system but not cause unwanted toxic side effects.
- a variant or fragment of the peptide of SEQ ID NO 1 in the fourth aspect of the invention.
- full length peptide of SEQ ID NO 1 is capable of inducing cellular lysis and stimulation of the inflammatory response in epithelial cells.
- These side effects may therefore be avoided by using a variant sequence which is immunogenic, or a fragment of SEQ ID NO 1, in particular one which contains at least SEQ ID NO 2 or SEQ ID NO 3 as described above.
- the peptide of SEQ ID NO 1 interacts with phospholipids, omission of the dibasic (lysine, arginine) C-terminal head of the peptide may mitigate any unwanted toxic effects.
- a specific binding partner for a peptide as described above for use in therapy, in particular where the therapy is the treatment or prevention of infection by Candida albicans.
- the specific binding partner may be used as a vaccine in a vaccination method that may be prophylactic or therapeutic.
- a vaccination method that may be prophylactic or therapeutic.
- the amount of specific binding partner administered will vary depending upon factors such as the size and health of the patient, the nature of the condition being treated etc. in accordance with normal clinical practice.
- a dosage in the range of from 1 to 50 mg/Kg, for instance from 2-30mg/Kg such as from 5-10mg/Kg would produce a suitable therapeutic or protective effect.
- a seventh aspect of the invention provides a pharmaceutical composition comprising a peptide as described above and a pharmaceutically acceptable carrier.
- An eighth aspect of the invention provides a pharmaceutical composition comprising a specific binding partner for a peptide as described above and a pharmaceutically acceptable carrier.
- Suitable pharmaceutical compositions will be in either solid or liquid form. They may be adapted for administration by any convenient route, such as parenteral, oral, vaginal or topical administration or for administration by inhalation or insufflation.
- the pharmaceutical acceptable carrier may include diluents or excipients which are physiologically tolerable and compatible with the active ingredient.
- compositions are prepared for injection, for example either subcutaneously or intravenously. They may be liquid solutions or suspensions, or they may be in the form of a solid that is suitable for solution in, or suspension in, liquid prior to injection. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH-buffering agents, and the like.
- Oral formulations will be in the form of solids or liquids, and may be solutions, syrups, suspensions, tablets, pills, capsules, sustained-release formulations, or powders.
- Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
- Topical formulations will generally take the form of suppositories or intranasal aerosols.
- traditional binders and excipients may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient.
- Peptides of the first aspect and specific binding partners of the second aspect of the invention may, if required, be produced using recombinant methods.
- nucleic acids that encode either the peptide or specific binding partner are prepared and these form a ninth aspect of the invention.
- nucleic acids may be incorporated into a suitable expression vector or plasmid, which is then used to transform a cell and in particular a prokaryotic cell.
- a suitable nucleic acid that encodes the peptide of SEQ ID NO 1 may correspond to a nucleic acid sequence that occurs naturally in strains of C. albicans strains.
- the nucleic acid is designed so that it is 'codon optimised' for the expression host being used in the recombinant production method. This should ensure efficient and effective production.
- the design and preparation of such nucleic acids will be apparent to the skilled person using techniques conventional in the art.
- a recombinant cell that has been transformed with such a nucleic acid forms a tenth aspect of the invention.
- Suitable cells will be conventional expression hosts such as E.coli and Pichia pastoris
- An eleventh aspect of the invention provides a method for producing a peptide as described above, or a specific binding partner therefor, which method comprises culturing a recombinant cell as described above and recovering said peptide or specific binding partner therefrom.
- the peptides of the first aspect and the specific binding partners of the second aspect of the invention may also be useful in diagnosis of pathogenic invasive C. albicans infection.
- C. albicans forms part of the commensal flora and so may be found in most individuals at low levels, for example of up to 800 organisms per ml sample.
- invasive or pathogenic infections may arise, in particular in immunocompromised individuals, and in such cases, the level of C. albicans increases dramatically or there is 'overgrowth'.
- albicans produces visible symptoms, it would be helpful if tests could be provided that allow for early diagnosis of such infection as this will allow treatment to be started before the infection escalates to a more dangerous systemic infection, or for the diagnosis of invasive pathogenic infection in organs which may not be examined easily such as the intestine.
- a method for diagnosis of pathogenic invasive infection by C. albicans comprising contacting a sample from an individual with a peptide as described above or a specific binding partner therefor, and detecting whether the sample contains moieties that interact with said peptide or specific binding partner at a sufficient level to indicate a pathogenic invasive infection.
- Detection of high levels of the peptide of the invention and in particular a peptide of SEQ ID NO 1 in a sample may be indicative of an overgrowth of C. albicans in the individual, leading to the symptoms of candidiasis.
- This may be determined by using a specific binding partner for the peptide to capture it.
- the specific binding partner is suitably either directly or indirectly labelled so as to detect or visualise the peptide in a quantitative or semi-quantitative manner.
- an elevated level of specific binding partner, and in particular, antibodies to the peptide of SEQ ID NO 1 present in the sample can also indicate that an overgrowth of Candida has occurred and that pathogenic invasive infection may result.
- the diagnostic method will typically utilise a peptide of the invention to bind with antibodies in the sample.
- the peptide may be immobilised or labelled to assist in the capture and/or detection of the antibodies in the sample.
- the sample used in the method may be any suitable biological sample including a blood, serum, sputum, saliva or mucosal swabs for instance oral or vaginal swabs, but may also include biopsy samples such as intestinal tissue samples.
- the levels of peptide or specific binding partner that is indicative of a pathogenic invasive infection or Candida 'overgrowth' rather than the presence of a non-damaging commensal species will vary depending upon factors such as the nature of the sample and the particular patient being examined and the particular technique used to carry out the assay, but will generally be determinable in a particular case in accordance with conventional clinical techniques.
- levels of C. albicans of up to about 800cells/ml saliva sample may be acceptable as a commensal background, but levels significantly higher than this, in particular at least an order of magnitude greater than this, can be indicative of overgrowth and pathogenic invasive infection. Detection of levels of the peptide of the invention at levels that equate to this cellular population of Candida species would be a cause for concern.
- Methods include those conventionally known in the art such as immunoassays, for instance, enzyme-linked immuno sorbent assays (ELISA) but may also include multiplex bead assays, immunohistochemistry or immunofluorescence. Such methods are well known in the art.
- immunoassays for instance, enzyme-linked immuno sorbent assays (ELISA)
- ELISA enzyme-linked immuno sorbent assays
- multiplex bead assays immunohistochemistry or immunofluorescence.
- Kits for carrying out such methods form a further aspect of the invention.
- the invention further provides a kit for diagnosing a pathogenic invasive infection by C. albicans, said kit comprising a peptide as described above or a specific binding partner therefor, and means for detecting complexes formed between said peptide or specific binding partner and moieties in the sample.
- detection means will include label means.
- the label means is suitably one in which the intensity of the signal developed can be related to the concentration of the moiety being detected as this will allow a distinction to be made between levels of C. albicans which is commensal and a level at which disease may result.
- Suitable label means may be indirect label means which allow signals to develop following a subsequent reaction such as a chemical reaction. These will include enzymatic labels such as peroxidase labels and in particular horseradish peroxidase. Alternatively, labels may include direct labels such as visible plastic labels, fluorescent labels like fluorescein or derivatives thereof, rhodamine or derivatives as described above, as well as radiolabels such as 125 I labels. The labels may be bound to or otherwise associated with the peptide of the invention or the specific binding partner therefor, or they may be linked to a secondary detection moiety such as a secondary antibody or other binding moiety. The precise form the detection means will take will vary depending upon the detection technique employed.
- detection means may include solid supports such as 96-well plates or beads that may be ferromagnetic in nature.
- the solid supports will generally have binding moieties for either the peptide of the first aspect or the specific binding partner of the second aspect immobilised thereon.
- binding moieties are specific for the peptide of the invention, for instance they are specific binding partners of the second aspect of the invention
- incubation of the sample in contact with the solid support will result in capture of the peptides on the support.
- a secondary detection antibody that also binds the peptide but carries a label which is either directly or indirectly detectable.
- Directly detectable labels may comprise visible labels such as fluorescent or radiolabels as described above. Indirect labels may be detected in subsequent reactions such as horseradish peroxidase that is carried by the secondary detection antibody or by a tertiary detection antibody that binds to the immobilised secondary antibody.
- binding moieties on the solid support specific for a specific binding partner and in particular an antibody to the peptide of the invention, they will generally comprising a peptide of the first aspect of the invention.
- incubation of the sample in contact with the solid support will result in capture of antibodies to the peptide on the support.
- the presence of immobilised antibody can similarly be detected by application of a secondary detection antibody that binds the antibody but carries a label which is either directly or indirectly detectable.
- kits will suitably contain labelled reagents such as suitable stains or dyes that are targeted to the required moiety and in particular the peptide of the invention, as a result of attachment to a suitable specific binding partner.
- labelled reagents such as suitable stains or dyes that are targeted to the required moiety and in particular the peptide of the invention, as a result of attachment to a suitable specific binding partner.
- the sample will be prepared in the usual way.
- a tissue sample is collected, if necessary sectioned and fixed onto a support such as microscope slide whereupon the labelled reagent is administered to the slide so as to visulalise the target moiety and in particular the peptide of SEQ ID NO 1.
- the kit may comprise one or more additional elements used in immunohistochemical or immunofluorescence method.
- blocking agents to reduce background signal caused by non-specific binding of the labelled reagent, which blocking agents may include serum, bovine serum albumin or gelatin.
- the peptide of SEQ ID NO 1 since the peptide of SEQ ID NO 1 has been identified as a cytotoxic element in C. albicans infections, it can be used to develop drugs and other therapies that specifically target this peptide. It may therefore form a useful tool in the screening of antifungal compounds. Screening methods of this type form a further aspect of the invention.
- Screening methods may take a variety of forms. Typically however, compounds under test will be contacted with a peptide of the invention and in particular a peptide of SEQ ID NO 1 and any interaction between the peptide and the compound will be monitored.
- the interaction may take place in a vessel or well for instance of a 96-well plate, and the interaction detected using for example, a change in reflectance of polarised light caused by binding.
- the interaction may take place at a surface at which one of the peptide or the target reagent is immobilised and under conditions where interaction may be detected using techniques such as surface plasmon resonance and the like.
- C. albicans gene deletion mutants lacking ECE1, as well as revertant mutant strains were created.
- C. albicans gene deletion cassettes were generated using the PCR-based method described by Dalle F et al. Cellular Microbiology 2010; 12:248-71 .
- Primers ECE1-FG and ECE1-RG as shown below as SEQ ID NO 4 and 5 respectively, were used to amplify the HIS1 and ARG4 markers from plasmids pFA-HIS1 and pFA-ARG4, respectively.
- the C. albicans strain BWP17 Wachtler B, et al.
- ECE1 open reading frame plus upstream and downstream intergenic regions were amplified with primers ECE1-RecF3k (SEQ ID NO 6) and ECE1-RecR (SEQ ID NO 7) and cloned into plasmid CIp10 at Mlu I and Sal I sites, yielding plasmid CIp10-ECE1.
- This plasmid was transfomed into the uridine auxotrophic ece1 ⁇ - deletion strain, yielding the ece1 ⁇ / ⁇ - ECE1 complemented strain.
- LDH lactate dehydrogenase
- Ecel can be proteolytically processed by Kex2 into eight peptide fragments ( O. Bader et al. BMC Microbiology 2008, 8:115 ).
- Figure 2 illustrates the structure of Ecel and the proposed resultant peptide fragments following proteolytic processing as well as its phylogenic relationship with orthologues in C. dubliniensis and C. tropicalis (note that ECE1 orthologues are only found in these two fungal species).
- Each of the individual C. albicans peptides were synthesised by ProteoGenix using fmoc solid phase peptide synthesis technology.
- Example 1 The method of Example 1 was then repeated using a 1:1 mixture of peptides (1-7) of Figure 2 on human TR146 oral epithelial cells at various concentrations (250 ⁇ g/ml, 125 ⁇ g/ml, 62.5 ⁇ g/ml, 31.25 ⁇ g/ml, 15.625 ⁇ g/ml and 7.8 ⁇ g/ml of each individual peptide within the mixture) or peptide 3 (SEQ ID NO 1) alone in the presence of the ece1 ⁇ mutant C. albicans. Peptide 8 could not be included, as this peptide was insoluble. After incubations for 24 hours, the damage was assessed by measuring LDH release as before. The results are shown in Figure 3A . This shows that peptide 3 (designated Ece1-III in the Figure) produced similar levels of damage to the combination at a concentration of 250 ⁇ g/ml.
- Each individual peptide (at a final concentration of 30 ⁇ g/ml) was incubated with 1 ⁇ 10 7 human erythrocytes in a volume of 150 ⁇ l. After incubation for 1 hour at 37°C, haemolysis was assayed by measuring haemoglobin release, as indicated by absorbance at 541nm, normalised to a 100% lysis-water control.
- Pore-forming toxins are generally strong activators of inflammatory responses.
- recognition of C. albicans hyphae resulted in the activation of the mitogen-activated protein kinase (MAPK) p38 signalling pathway and the c-Fos transcription factor, which in turn activates proinflammatory cytokine production ( Moyes DL, et al.: Cell Host Microbe 2010, 8:225-235 ,).
- An extensive screen of >100 C . albicans mutants was carried out using protocols described in this reference and also Moyes DL, et al. PLoS ONE 2011, 6:e26580 ; Murciano C. et al.
- Ece1-III As the region of Ecel responsible for cellular lysis and the activation of immune responses, the applicants next investigated the precise functional requirements of the Ece1-III amino acid sequence ( Figure 8A ). Accordingly, individual peptide fragments corresponding to internal regions of Ece1-III were constructed (WTSA peptides 1-6 (SEQ ID NOS 8-11, 3 and 12 respectively: Figure 8B ). The sequence of each WTSA peptide was chosen to facilitate a detailed examination of each of the internal amyloidogenic regions of Ece1-III, either alone (WTSA peptides 1, 2, 4 and 5), or in combination (WTSA 3).
- the p38/c-Fos pathway is activated via the interaction of C. albicans hyphae with the surface receptor EGFR (epidermal growth factor receptor), as blocking EGFR activation also blocks c-Fos activation ( Figure 11A ).
- Biacore binding assays show that Ece1-III (of SEQ ID NO 1), but not other parts of the Ecel protein, directly interact with EGFR with high affinity ( Figure 11B ) and that blocking EGFR abolishes the ability of Ece1-III to activate c-Fos ( Figure 11C ). Furthermore, blocking EGFR also reduced/abolished activation of all three MAPK signalling pathways (p38, JNK and ERK1/2) ( Fig.
- Ece1-III consists of a predicted alpha helix with a dibasic (lysine, arginine) C-terminal head, the applicants predicted that these cationic, positively charged residues may interact with negatively charged phospholipids present in target membranes.
- Ece1-III was used to probe a phospholipid array (PIP Strip membrane). Binding was assessed by hybridisation with anti-Ece1-III antibody, followed by detection with anti-rabbit antibody conjugated to horse radish peroxidase. The results are shown in Figure 13 .
- Ece1-III interacts with Phosphatidylinositol-3-phosphate, Phosphatidylinositol-4-phosphate, Phosphatidylinositol-5-phosphate, Phosphatidylinositol-3,4-phosphate, Phosphatidylinositol-3,5 -phosphate, Phosphatidylinositol-4,5-phosphate, Phosphatidylinositol-3,4,5-phosphate, Phosphatidic acid and Phosphatidylserine, with binding to Phosphatidylinositol-3-phosphate being particularly robust ( Figure 13 ).
- Ece1-III did not interact with Lysophosphatidic acid, Lysophosphatidylcholine, Phosphatidylinositol, Phosphatidylethanolamine, Phosphatidylcholine or Sphingosine-1-phosphate. Therefore, insertion of Ece1-III into target membranes (pore formation) may be mediated by interactions with phospholipids.
- Ece1-III Given the importance of Ece1-III in killing epithelial cells, the applicants examined whether it also plays a role in immune escape of C. albicans from macrophages.
- C. albicans yeast cells are phagocytosed by macrophages, but rapidly germinate and escape the macrophage via hypha formation.
- Ecel is involved in this process, wild type, ece1 ⁇ , and ece1 ⁇ / ⁇ - ECE1 cells were coincubated with macrophages and the following parameters measured: phagocytosis rates, length of hyphae, escape from macrophages, and damage of macrophages.
- mice were first immunosuppressed with cortisone acetate prior to administration of wild-type (parental) C. albicans (BWP17), a ece1 ⁇ null mutant and ece1 ⁇ / ⁇ - ECE1 revertant strain into the oral cavity. After four days, fungal burdens, fungal invasion, tissue damage and immune cell recruitment was determined in tongue tissues.
- mice infected with the ece1 ⁇ null mutant were found in mice infected with the ece1 ⁇ null mutant as compared with the wild-type (BWP17) or the ece1 ⁇ / ⁇ - ECE1 revertant strains, and in many cases the ece1 ⁇ null mutant could not be recovered from mice ( Figure 16 A) .
- Histological analysis of mouse tongues in both the wild-type (BWP17) and ece1 ⁇ / ⁇ - ECE1 revertant strain showed multiple foci of infection that were associated with inflammatory immune cells (neutrophils) and extensive local tissue damage ( Figure 16 B-D ).
- mice infected with the ece1 ⁇ null mutant showed no evidence of any foci of invasion, tissue damage or inflammation and no evidence of C. albicans was detectable ( Figure 16 E) . Therefore, Ecel is essential for successful mucosal infection, damage induction and immune activation in this model.
- the applicants also determined the effect of administering full length His-tagged Ecelp and Ece1-III in a Drosophila melanogaster (fruit fly) model. All flies injected with full length His-tagged Ecelp and Ece1-III displayed signs of paralysis, with only 17.5% and 10% recovering after 24 hours, as compared with the negative control Ecel-II (peptide 2) which showed no signs of paralysis ( Figure 17 ). This indicates that Ece1-III may have a direct or indirect neurotoxic effect.
- Ecel and its active component Ece1-III
- Ece1-III has a dual functional role, by acting both as a pore-forming toxin that damages host cells and as an activator of immune responses. Damage of host cells and uncontrolled immune activation are the hallmarks of several diseases caused by C. albicans, which can often lead to death (45- 76% mortality) during systemic infections. Therefore, neutralisation of Ece1-III will prevent not only host damage during C. albicans infections but also deleterious inflammatory responses. This indicates that Ece1-III represents a new therapeutic target to treat C. albicans infections.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
- The present invention relates to moieties selected from a specific type of peptide and binding partners such as antibodies therefor, which have applications in diagnosis and therapy. Methods for using these moieties in diagnosis and therapy as well as in processes for screening for therapeutic compounds are also part of the invention. The isolated peptide and specific binding partners therefor are novel and form further aspects of the invention.
- Candida species are the most common fungal pathogens of humans and the causative agents of oral, gastrointestinal and vaginal candidiasis, giving rise to severe morbidity in millions of individuals worldwide. Vaginal candidiasis affects ∼75% of women at least once during fertile age, equating to ∼30 million infection episodes/year (3x more than tuberculosis and 8x more than HIV: WHO 2007). Candida infections are also the 3rd most common hospital-acquired bloodstream infection, making Candida species more medically-important than most bacterial infections including Enterococci (E. coli) and Pseudomonas spp. Systemic candidiasis is fatal (30-50% mortality) with ∼300,000 cases/year of candidaemia, equating to ∼100,000 deaths/year. Furthermore, Candida infections are the most common oral manifestation of HIV infection, with 50% of HIV+ patients and 90% AIDS patients suffering from oral candidiasis. With ∼4 million cases of HIV/year, this equates to ∼2 million oral candidiasis cases/year. Indeed, one of the biggest killers of the immunocompromised population is fungal infection. In the USA, yearly healthcare costs for fungal infections are $2.6 billion, of which Candida infections account for $1.8 billion. EU healthcare costs are estimated to be similar. Therefore, Candida pathogens carry an immense health burden and represent a major socio-economic challenge for worldwide communities.
- Candida albicans is a member of the normal human microbiome. Although typically a commensal of the oral cavity, gastrointestinal and urinogenitary tracts, C. albicans is also an extremely frequent cause of superficial infections such as vaginitis. Moreover, common iatrogenic procedures, such as gastrointestinal surgery, implantation of a central venous catheter or antibiotic treatment are major risk factors for disseminated candidiasis. This form of systemic candidiasis is now the third most common cause of nosocomial bloodstream infections and the mortality of severe sepsis caused by Candida species is over 50% in some patient groups.
- Identifying new epithelial and fungal targets that stimulate protective host immunity will ultimately have major implications for global health.
- C. albicans virulence relies on a number of factors, including morphological plasticity, the expression of adhesins and invasins, robust stress responses, immune evasion, metabolic flexibility and nutrient acquisition. However, it remains unclear, how C. albicans causes damage.
- The mechanisms by which C. albicans damages host cells have been considered to be multi-factorial, and presumed to rely on a combination of adhesion, invasion, hyphal extension, turgor pressure and the secretion of hydrolytic enzymes. Although toxin production by C. albicans has long been postulated and the culture supernatants of C. albicans hyphae shown to exhibit haemolytic activity, the mechanism underlying C. albicans ability to lyse host cells has remained elusive. It is clear, however, that hyphae are essential for adhesion, invasion and damage. Thus, damage is caused by hyphae and/or a hyphal associated factor.
- The gene ECE1 (extent of cell elongation 1) was first identified two decades ago due to its heightened expression during hypha formation. However, deletion of ECE1 did not affect hypha formation in C. albicans and phenotypic differences between C. albicans wild type and ECE1 deletion strains have not been reported. Despite this, ECE1 expression has been used as a marker for hypha formation in multiple independent studies and ECE1 is one of the most strongly expressed genes during hyphal formation. In fact, ECE1 is within a small group of core hyphal associated genes. It has previously been reported that recombinant Ecel is processed by the protease, Kex2, at lysine/arginine residues. However, the function of Ecel has never been shown.
- Currently, the gold standard for treating fungal infections is the use of antifungal drugs, which predominantly target either the cell wall (echinocandins), cell membrane (polyenes) or ergosterol synthesis (azoles). However, the continuing increase in Candida infections together with increasing drug resistance highlights the need to discover new and better agents that target either (i) epithelial processes that recognise and normally restrict these potentially life-threatening pathogens to mucosal surfaces or (ii) fungal determinants that promote infection and/or mediate immune activation and protective immunity. Despite this, there are no vaccine candidates or immune-based intervention strategies for combating Candida infections. Likewise, there are no commercial drugs that specifically target mucosal fungal infections.
- The applicants have found that Ecel plays a key role in host cell activation and damage, as demonstrated by the fact that deletion of ECE1 renders C. albicans unable to damage or activate inflammatory responses in human epithelial cells. Moreover, the applicants have demonstrated that a single peptide product of proteolytic processing of Ecel acts as a peptide toxin, in particular, a pore-forming toxin: the first such described in a human fungal pathogen. By targeting this single peptide it is possible to prevent both host damage (fungus driven) and manipulate immunity to induce protection (host driven). To date, no other Candida protein exhibits these phenotypes and no other approach can address both fungal and host aspects.
- This gives rise to a number of diagnostic and therapeutic applications for this peptide and also for specific binding partners for it, as well as for the discovery and development of anti-fungal compounds that target this specific peptide.
- According to a first aspect of the present invention there is provided an optionally labelled peptide comprising
SEQ ID NO 1 - SIIGIIMGILGNIPQVIQIIMSIVKAFKGNKR (SEQ ID NO. 1) or a variant thereof, or an immunogenic fragment of either of these; or a labelled form thereof.
- As used herein, the expression 'variant' refers to a peptide sequence in which the amino acid sequence differs from the sequence of
SEQ ID NO 1 in that one or more amino acids within the sequence are substituted for other amino acids. However, the variant produces a biological effect which is similar to that ofSEQ ID NO 1. In particular, any variant will interact with the surface receptor EGFR (epidermal growth factor receptor) to give rise to activation of an immune response and/or immunoglobulins and in particular antibodies that are produced in response to said variants will cross-react withSEQ ID NO 1. Alternatively or additionally, the variant will be damage inducing in host cells, for example by acting as pore forming agents. - Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid in the same class with broadly similar properties. Non-conservative substitutions are where amino acids are replaced with amino acids of a different type or class.
- Amino acid classes are defined as follows:
Class Amino acid examples Nonpolar: A, V, L, I, P, M, F, W Uncharged polar: G, S, T, C, Y, N, Q Acidic: D, E Basic: K, R, H. - As is well known to those skilled in the art, altering the primary structure of a peptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This is so even when the substitution is in a region which is critical in determining the peptide's conformation.
- Non-conservative substitutions may also be possible provided that these do not interrupt the function of the peptide and in particular its ability to cross-react with immunoglobulins that react with
SEQ ID NO 1. - Broadly speaking, fewer non-conservative substitutions will be possible without altering the biological activity of the polypeptides.
- Particular variants may include peptides encoded by orthologues or paralogues of the gene sequence that encodes the peptide of
SEQ ID NO 1 in C. albicans. Particular variant sequences are orthologues from C. dubliniensis and C. tropicalis as shown inFigure 2 hereinafter. - In general, variants will have amino acid sequences that will be at least 70%, for instance at least 71%, 75%, 79%, 81%, 84%, 87%, 90%, 93% or 96% identical to
SEQ ID NO 1. Identity in this context may be determined using the BLASTP computer program withSEQ ID NO 1 as the base sequence. The BLAST software is publicly available at http://blast.ncbi.nlm.nih.gov/Blast.cgi (accessible on 12 March 2009). - Variants may also include addition sequences such as tag sequences that may be used for instance in facilitating purification of the peptide or in detection of it. Thus for instance, the variant may further comprise an affinity tag such as chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), FLAG, myc, biotin or a poly(His) tag as are known in the art. In another embodiment, the variant may comprise a fluorescent protein such as green fluorescent protein (GFP).
- When the peptide is for use in diagnostics or screening of anti-fungal proteins, it may be helpful to label the peptide, for example with a chemical label such as a fluorescent or radio label. There are a wide range of such labels available commercially, but examples include fluorescein and derivatives such as fluorescein isothiocyanates (FITC), carboxyfluorescein succinimidyl esters, fluorescein dichlorotriazine (DTAF) and 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE), rhodamine and derivatives such as carboxytetramethylrhodamine (TAMRA), tetramethylrhodamine (TMR) and its isothiocyanate derivative (TRITC), sulforhodamine, Texas Red, Rhodamine Red and the dyes available under the trade name Alexa.
- These labels may be incorporated into the peptide using conventional methods.
- The term "fragment" as used herein refers to any portion of the amino acid sequence of
SEQ ID NO 1 which has biological function in common withSEQ ID NO 1. (e.g. damage-inducing, immunomodulatory or is immunogenic, for instance an epitopic fragment) and which reacts with specific binding partners forSEQ ID NO 1. Suitable fragments will include deletion mutants comprising up to 31 amino acids, for example at least 7 amino acids, such as at least 10, for instance at least 15, such as at least 20, more suitably at least 30 amino acids. - Notably,
Seq ID NO 1 includes two segments that contain sequences with high amyloidogenic potential (underlined), which may be involved in cell interactions and activation due to their hydrophobic nature and ability to potentially form α-helices. Particular variants or fragments ofSEQ ID NO 1 will contain at least one of said sequences which are represented below asSEQ ID NO 2 andSEQ ID NO 3 respectively.IIGIIMGIL (SEQ ID NO. 2) QVIQIIMSIV (SEQ ID NO. 3) - In a particular embodiment however, the peptide is a peptide of SEQ ID NO. 1. The peptide is in isolated or purified form and in particular is free of at least some and preferably all other peptides obtainable by Kex2 protease cleavage of the Ecel protein of C. albicans. Although the peptide may be isolated from C. albicans that has been subject to Kex2 protease digestion, in a particular embodiment, the peptide is prepared synthetically using conventional preparation methods.
- As discussed above, peptides of the invention and in particular the peptide of
SEQ ID NO 1 has been found to be immunogenic. Thus in a second aspect of the present invention there is provided a specific binding partner for a peptide as described above; or a labelled form thereof. Particular specific binding partners are immunoglobulins, such as an antibody or a binding fragment thereof. Examples of suitable binding fragments of antibodies include Fab, Fab', F(ab)2, F(ab')2 and FV, VH and VK fragments. - Antibodies may be polyclonal or monoclonal but in a particular embodiment, the antibodies are monoclonal antibodies.
- Antibodies can be prepared using conventional methods involving inoculation of an animal such as mouse or guinea pig with a peptide of the first aspect of the invention and harvesting antibodies from the blood thereof. Monoclonal antibodies can be obtained therefrom by fusing antibody producing cells such as spleen cells from the inoculated animal with a hybridoma cell, culturing this cell and harvesting monoclonal antibodies therefrom.
- Where the antibody is used in diagnostic or screening applications, it may be chemically labelled to facilitate detection. Suitable labels will be similar to those described above for the peptides of the invention. However, the antibody may be detectable using a secondary antibody which is modified so as to be detectable using a development reaction, for example because it includes an enzymatic label, as is conventional in the art.
- The peptide of the invention has therapeutic applications. Therefore, a third aspect of the invention provides a peptide as described above for use in therapy, and in particular for the treatment or prevention of infection by Candida albicans. In particular, the therapy is for the treatment or prevention of oral, gastrointestinal or mucosal and in particular vaginal infection by Candida albicans.
- In order to achieve these therapeutic effects, a non-toxic amount of a peptide as described above or a pharmaceutically acceptable composition comprising it is administered to a subject, such as a human or animal. The non-toxic amount is sufficient to produce an immune response that is protective against C. albicans infection. Thus the peptide may be used as a vaccine in a vaccination method. Such a method forms a fourth aspect of the invention.
- The amount of peptide administered will vary depending upon factors such as the size and health of the patient, the nature of the condition being treated etc. in accordance with normal clinical practice. Typically, a dosage in the range of from 1µg-50mg/Kg such as from 1-50µg/Kg but in particular from 1-50mg/Kg, for instance from 2-20 mg/Kg, such as from 5-15 mg/Kg would be expected to produce a suitable immune response. Since the peptide of
SEQ ID NO 1 has been found to have cytotoxic effects however, care must be taken to ensure that the dosage is sufficient to prime the immune system but not cause unwanted toxic side effects. - One way of avoiding such side effects is to use a variant or fragment of the peptide of
SEQ ID NO 1 in the fourth aspect of the invention. As described hereinbelow, the applicants have found that full length peptide ofSEQ ID NO 1 is capable of inducing cellular lysis and stimulation of the inflammatory response in epithelial cells. These side effects may therefore be avoided by using a variant sequence which is immunogenic, or a fragment ofSEQ ID NO 1, in particular one which contains at leastSEQ ID NO 2 orSEQ ID NO 3 as described above. Furthermore, the applicants have found that the peptide ofSEQ ID NO 1 interacts with phospholipids, omission of the dibasic (lysine, arginine) C-terminal head of the peptide may mitigate any unwanted toxic effects. - An alternative way of avoiding unwanted side effects is to use the specific binding partners and in particular the antibodies of the second aspect of the invention in a passive immunisation regime. Thus in a fifth aspect of the invention, there is provided a specific binding partner for a peptide as described above for use in therapy, in particular where the therapy is the treatment or prevention of infection by Candida albicans.
- As before, in order to achieve these effects, an effective amount of the specific binding partner and in particular the antibody, or a pharmaceutical composition containing it is administered to a subject in need thereof. Thus the specific binding partner may be used as a vaccine in a vaccination method that may be prophylactic or therapeutic. Such a method forms a sixth aspect of the invention.
- Again, the amount of specific binding partner administered will vary depending upon factors such as the size and health of the patient, the nature of the condition being treated etc. in accordance with normal clinical practice. Typically, a dosage in the range of from 1 to 50 mg/Kg, for instance from 2-30mg/Kg such as from 5-10mg/Kg would produce a suitable therapeutic or protective effect.
- For administration to subjects, the peptide or its specific binding partner is suitably administered in the form of a pharmaceutical composition. Thus a seventh aspect of the invention provides a pharmaceutical composition comprising a peptide as described above and a pharmaceutically acceptable carrier.
- An eighth aspect of the invention provides a pharmaceutical composition comprising a specific binding partner for a peptide as described above and a pharmaceutically acceptable carrier.
- Suitable pharmaceutical compositions will be in either solid or liquid form. They may be adapted for administration by any convenient route, such as parenteral, oral, vaginal or topical administration or for administration by inhalation or insufflation. The pharmaceutical acceptable carrier may include diluents or excipients which are physiologically tolerable and compatible with the active ingredient.
- Parenteral compositions are prepared for injection, for example either subcutaneously or intravenously. They may be liquid solutions or suspensions, or they may be in the form of a solid that is suitable for solution in, or suspension in, liquid prior to injection. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH-buffering agents, and the like.
- Oral formulations will be in the form of solids or liquids, and may be solutions, syrups, suspensions, tablets, pills, capsules, sustained-release formulations, or powders. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
- Topical formulations will generally take the form of suppositories or intranasal aerosols. For suppositories, traditional binders and excipients may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient.
- Peptides of the first aspect and specific binding partners of the second aspect of the invention, may, if required, be produced using recombinant methods. For this purpose, nucleic acids that encode either the peptide or specific binding partner are prepared and these form a ninth aspect of the invention.
- Such nucleic acids may be incorporated into a suitable expression vector or plasmid, which is then used to transform a cell and in particular a prokaryotic cell. A suitable nucleic acid that encodes the peptide of
SEQ ID NO 1 may correspond to a nucleic acid sequence that occurs naturally in strains of C. albicans strains. However, in a particular embodiment, the nucleic acid is designed so that it is 'codon optimised' for the expression host being used in the recombinant production method. This should ensure efficient and effective production. The design and preparation of such nucleic acids will be apparent to the skilled person using techniques conventional in the art. - A recombinant cell that has been transformed with such a nucleic acid forms a tenth aspect of the invention.
- Suitable cells will be conventional expression hosts such as E.coli and Pichia pastoris An eleventh aspect of the invention provides a method for producing a peptide as described above, or a specific binding partner therefor, which method comprises culturing a recombinant cell as described above and recovering said peptide or specific binding partner therefrom.
- However, the peptides of the first aspect and the specific binding partners of the second aspect of the invention may also be useful in diagnosis of pathogenic invasive C. albicans infection. C. albicans forms part of the commensal flora and so may be found in most individuals at low levels, for example of up to 800 organisms per ml sample. However, as discussed previously, invasive or pathogenic infections may arise, in particular in immunocompromised individuals, and in such cases, the level of C. albicans increases dramatically or there is 'overgrowth'. Although in many cases, pathogenic invasive oral or vaginal infection of C. albicans produces visible symptoms, it would be helpful if tests could be provided that allow for early diagnosis of such infection as this will allow treatment to be started before the infection escalates to a more dangerous systemic infection, or for the diagnosis of invasive pathogenic infection in organs which may not be examined easily such as the intestine.
- In an eleventh aspect of the invention, there is provided a method for diagnosis of pathogenic invasive infection by C. albicans, said method comprising contacting a sample from an individual with a peptide as described above or a specific binding partner therefor, and detecting whether the sample contains moieties that interact with said peptide or specific binding partner at a sufficient level to indicate a pathogenic invasive infection.
- Detection of high levels of the peptide of the invention and in particular a peptide of
SEQ ID NO 1 in a sample may be indicative of an overgrowth of C. albicans in the individual, leading to the symptoms of candidiasis. This may be determined by using a specific binding partner for the peptide to capture it. The specific binding partner is suitably either directly or indirectly labelled so as to detect or visualise the peptide in a quantitative or semi-quantitative manner. - Similarly, an elevated level of specific binding partner, and in particular, antibodies to the peptide of
SEQ ID NO 1 present in the sample can also indicate that an overgrowth of Candida has occurred and that pathogenic invasive infection may result. In this case, the diagnostic method will typically utilise a peptide of the invention to bind with antibodies in the sample. The peptide may be immobilised or labelled to assist in the capture and/or detection of the antibodies in the sample. - The sample used in the method may be any suitable biological sample including a blood, serum, sputum, saliva or mucosal swabs for instance oral or vaginal swabs, but may also include biopsy samples such as intestinal tissue samples.
- The levels of peptide or specific binding partner that is indicative of a pathogenic invasive infection or Candida 'overgrowth' rather than the presence of a non-damaging commensal species will vary depending upon factors such as the nature of the sample and the particular patient being examined and the particular technique used to carry out the assay, but will generally be determinable in a particular case in accordance with conventional clinical techniques. Typically however, levels of C. albicans of up to about 800cells/ml saliva sample may be acceptable as a commensal background, but levels significantly higher than this, in particular at least an order of magnitude greater than this, can be indicative of overgrowth and pathogenic invasive infection. Detection of levels of the peptide of the invention at levels that equate to this cellular population of Candida species would be a cause for concern.
- Methods include those conventionally known in the art such as immunoassays, for instance, enzyme-linked immuno sorbent assays (ELISA) but may also include multiplex bead assays, immunohistochemistry or immunofluorescence. Such methods are well known in the art.
- Kits for carrying out such methods form a further aspect of the invention. Thus the invention further provides a kit for diagnosing a pathogenic invasive infection by C. albicans, said kit comprising a peptide as described above or a specific binding partner therefor, and means for detecting complexes formed between said peptide or specific binding partner and moieties in the sample. The nature of the detection means will vary depending upon the particular technique being employed. In general, detection means will include label means. The label means is suitably one in which the intensity of the signal developed can be related to the concentration of the moiety being detected as this will allow a distinction to be made between levels of C. albicans which is commensal and a level at which disease may result.
- Suitable label means may be indirect label means which allow signals to develop following a subsequent reaction such as a chemical reaction. These will include enzymatic labels such as peroxidase labels and in particular horseradish peroxidase. Alternatively, labels may include direct labels such as visible plastic labels, fluorescent labels like fluorescein or derivatives thereof, rhodamine or derivatives as described above, as well as radiolabels such as 125I labels. The labels may be bound to or otherwise associated with the peptide of the invention or the specific binding partner therefor, or they may be linked to a secondary detection moiety such as a secondary antibody or other binding moiety. The precise form the detection means will take will vary depending upon the detection technique employed.
- For instance for immunoassays such as ELISA assays, detection means may include solid supports such as 96-well plates or beads that may be ferromagnetic in nature. In such cases, the solid supports will generally have binding moieties for either the peptide of the first aspect or the specific binding partner of the second aspect immobilised thereon.
- Where the binding moieties are specific for the peptide of the invention, for instance they are specific binding partners of the second aspect of the invention, incubation of the sample in contact with the solid support will result in capture of the peptides on the support. Once the sample has then been removed from the support for example by washing, the presence of immobilised peptide can be detected by application of a secondary detection antibody that also binds the peptide but carries a label which is either directly or indirectly detectable. Directly detectable labels may comprise visible labels such as fluorescent or radiolabels as described above. Indirect labels may be detected in subsequent reactions such as horseradish peroxidase that is carried by the secondary detection antibody or by a tertiary detection antibody that binds to the immobilised secondary antibody.
- Similarly where the binding moieties on the solid support specific for a specific binding partner and in particular an antibody to the peptide of the invention, they will generally comprising a peptide of the first aspect of the invention. In this case, incubation of the sample in contact with the solid support will result in capture of antibodies to the peptide on the support. Once the sample has then been removed from the support for example by washing, the presence of immobilised antibody can similarly be detected by application of a secondary detection antibody that binds the antibody but carries a label which is either directly or indirectly detectable.
- For immunohistochemical or immunofluorescence detection methods, kits will suitably contain labelled reagents such as suitable stains or dyes that are targeted to the required moiety and in particular the peptide of the invention, as a result of attachment to a suitable specific binding partner. In use, the sample will be prepared in the usual way. In particular, a tissue sample is collected, if necessary sectioned and fixed onto a support such as microscope slide whereupon the labelled reagent is administered to the slide so as to visulalise the target moiety and in particular the peptide of
SEQ ID NO 1. The kit may comprise one or more additional elements used in immunohistochemical or immunofluorescence method. These include the slide itself, fixing agent such as paraformaldehyde, detergent such as Triton® detergent for reducing surface tension and facilitating coverage by the labelled reagent, and blocking agents to reduce background signal caused by non-specific binding of the labelled reagent, which blocking agents may include serum, bovine serum albumin or gelatin. - In addition, since the peptide of
SEQ ID NO 1 has been identified as a cytotoxic element in C. albicans infections, it can be used to develop drugs and other therapies that specifically target this peptide. It may therefore form a useful tool in the screening of antifungal compounds. Screening methods of this type form a further aspect of the invention. - Screening methods may take a variety of forms. Typically however, compounds under test will be contacted with a peptide of the invention and in particular a peptide of
SEQ ID NO 1 and any interaction between the peptide and the compound will be monitored. The interaction may take place in a vessel or well for instance of a 96-well plate, and the interaction detected using for example, a change in reflectance of polarised light caused by binding. Alternatively, the interaction may take place at a surface at which one of the peptide or the target reagent is immobilised and under conditions where interaction may be detected using techniques such as surface plasmon resonance and the like. - The invention will now be particularly described by way of example with reference to the accompanying diagrams which are summarised as follows. However, it will be apparent to one skilled in the art that the specific details are not required in order to practice the invention. The following descriptions of specific embodiments of the present invention are presented for purposes of illustration and description. They are not intended to be exhaustive of or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in view of the above teachings. The embodiments are shown and described in order to best explain the principles of the invention and its practical applications, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated.
-
Figure 1 is a series of graph showing the results of an experiment to determine whether ECE1 is required for damage of a variety of host cells. Oral TR146 (A), gastrointestinal Caco (B) and vaginal (C) epithelial cells were infected with C. albicans wild type (wt), ece1Δ or ece1Δ,ECE1 strains for 24 hours and damage assayed by LDH release as described below. -
Figure 2 shows the structure of Ecel and phylogeny with other species. It shows the alignment of Ecel from C. albicans (SEQ ID NO 13) and orthologues in C. dubliniensis (SEQ ID NO 14) and C. tropicalis (SEQ ID NO 15) (which are the only three sequenced fungal species that encode Ecel). The bars below the alignment indicate that the peptides resulted from Kex2 digestion of the CaEce1.Only peptide 3 of C. albicans, C. dubliniensis and C. tropicalis form transmembrane α-helical structures. -
Figure 3 is a series of graphs showing the results of an experiment to demonstrate that a peptide of the invention is sufficient to lyse host epithelial cells. Mixtures of Ecel peptides at different concentrations or the peptide ofSEQ ID NO 1 alone were added to TR146 oral epithelial cells in the presence of the ece1Δ mutant, incubated for 24 hours and damage assessed by measuring LDH release (A). Subsequently the difference Ecel peptides were added alone (without C. ablicans cells) to TR146 (B) and vaginal A431(C) epithelia, incubated for 24 hours and damage assessed by measuring LDH release as described below. -
Figure 4 is a graph showing the results of an experiment to determine which of the Ecel peptides are haemolytic toxins where the peptide ofSEQ ID NO 1 ispeptide 3. Individual peptides were incubated with human erythrocytes for 1 hour and heamolysis assayed by measuring haemoglobin release (as measured by absorbance at 541nm, normalised to a 100% lysis control). -
Figure 5 shows the results obtained by scanning electron microscopy of an experiment to determine whether the peptide ofSEQ ID NO 1 forms pores in epithelial membranes. Oral epithelial (TR146) monolayers were incubated with 5µg/ml peptide 3 (SEQ ID NO 1) for 5 hours and pore formation assessed by scanning electron microscopy. Panel B shows a further magnified view of a region indicated in panel A. -
Figure 6 is a series of graphs showing the results of an experiment to demonstrate that the haemolytic activity of theEcel peptide 3 ofSEQ ID NO 1 is ion-dependent. The peptide was incubated with human erythrocytes with increasing concentrations of the divalent cation chelator EDTA (A) and haemolysis assayed by measuring haemoglobin release (absorbance at 541nm, normalised to a 100% lysis control). The inhibitory effect of 50mM EDTA was reversed by the addition of 50 or 100mM magnesium (B). -
Figure 7 is a series of graphs showing the results of experiments to investigate whether the peptide of the invention activates epithelial immunity and cFos. (A) Induction of c-Fos DNA binding activity in TR146 epithelial cells after 3 hours infection with ece1Δ/Δ null mutant, ece1Δ/Δ - ECE1 revertant and the BWP17 parent strain. (B) Production of cytokines by TR146 epithelial cells after 24 hour infection with ece1Δ/Δ null mutant, ece1Δ/Δ - ECE1 revertant, the BWP17 parent strain or uninfected cells. Data shown are the mean of 3 independent experiments. Error bars show SEM. * =p<0.05, **=p<0.01, ***=p<0.001. -
Figure 8 shows the amino acid sequences of Ece1-III and WTSA peptides where A shows the amino acid sequence of Ece1-III (SEQ ID NO 1). Amyloidogenic regions are shown in bold type; and B shows the amino acid sequences of WTSA peptides. Each individual WTSA peptide constitutes a partial fragment of full length Ece1-III. Amyloidogenic regions are shown in bold type. -
Figure 9 is a graph showing the results of analysis of WTSA peptide-induced damage to TR146 oral epithelial cells. Individual WTSA peptides (250 µg/ml) andWTSA 3 in combination with WTSA 6 (both peptides at 250 µg/ml) were added to confluent monolayers of TR146 oral epithelial cells and incubated for 24 hours at 37°C, 5% CO2. Following incubation, growth medium was removed and assayed for the presence of lactate dehydrogenase (LDH), a surrogate marker of cellular lysis. Dimethyl sulfoxide (DMSO) was used as a vehicle only (negative control). Full length Ece1-III (250 µg/mL) was used as the positive control. -
Figure 10 shows WTSA peptide-mediated activation of immune responses in TR146 oral epithelial cells. WTSA peptides 1-6 were added to confluent monolayers of TR146 oral epithelial cells at a final concentration of 250 µg/mL and incubated for 24 hours at 37°C, 5% CO2. Following incubation, growth medium was removed and secreted immunostimulatory cytokines were quantified by multiplex bead assay. Concentration of detected cytokines was expressed as picograms per millilitre (pg/mL). ND= not detected. -
Figure 11 is a series of graphs showing the results of experiments to investigate whether the peptide of the invention binds EGFR and activates c-Fos. (A) Induction of c-Fos DNA binding activity in TR146 epithelial cells after 3 hours infection with wild-type C. albicans cells, which were pre-treated for 1 hour with 4µM GW2974 (EGFR/Her2 inhibitor), 1µM PD153035 (EGFR inhibitor) or DMSO (vehicle control). (B) Sensorgram of fluid phase EGFR binding to immobilised Ece1-III ofSEQ ID NO 1 demonstrating high affinity binding. Injection of fluid phase components was at point A. (C) Induction of c-Fos DNA binding activity in TR146 epithelial cells after 3 hours infection with Ece1-III, which were pre-treated for 1 hour with 4µM GW2974 (EGRF/Her2 inhibitor), 1µM PD153035 (EGFR inhibitor) or DMSO (vehicle control). Data shown are the mean of 2(A) or 3 (C) independent experiments. Error bars show SEM. * =p<0.05, **=p<0.01, ***=p<0.001. -
Figure 12 is a set of graphs showing the effect of EGFR inhibition on epithelial cell signalling. Blocking EGFR signalling in oral epithelial cells (TR146) with Gefitnib (10µM) inhibits the activation of MAPK intracellular signalling in cells treated with Ecel-III (50µg/mL) for 2 hours as measured by decreases in levels of phosphorylated p38, JNK and ERK1/2 relative to the vehicle control (DMSO). -
Figure 13 shows the results of an assay to detect Ecel-III-phospholipid interactions. Ecel-III was used to probe a phospholipid array (PIP Strip membrane). Binding was assessed by hybridisation with anti-Ecel-III antibody, followed by detection with anti-rabbit antibody conjugated to horse radish peroxidase. -
Figure 14 is a series of graphs showing the results of an experiment to determine C. albicans -macrophage interactions. C. albicans strains were incubated with RAW264.7 macrophages for indicated times and the following parameters determined: (A) The number of phagocytosed fungal cells as a percentage of total number of fungal cells; (B) Hyphal length; (C) The percentage of outgrowing hyphae compared to the total number of internalised yeast mother cells. -
Figure 15 is a graph showing the results of an experiment to show that ECE1 is required for damage of macrophages. Indicated macrophage cell types were co-incubated with C. albicans cells for 24 hours (MOI of 1 for Raws, MOI of 10 for MDMs) and macrophage damage assessed by measuring lactate dehydrogenase release into the supernatant. -
Figure 16 shows the results of experiments showing the role of Ece1 in C. albicans mucosal pathogenesis. Infection of cortisone acetate-treated mice with wild-type (BWP17), ece1Δ null mutant or ece1Δ/Δ - ECE1 reverted strain (A) numbers of C. albicans fungi recovered per gram ofkidney 3 days post-infection. Fungal invasion, tissue damage and inflammatory cell infiltration oftongue tissue 3 days post-infection by (B) BWP17, (C) ece1Δ/Δ - ECE1 and (D) ece1Δ null mutant, indicating that the ece1Δ null mutant does not invade, damage or recruit inflammatory cells. (E)tongue section 3 days post-infection with BWP17 immunostained with MPO and CD15 markers of neutrophils. ** =P<0.01. -
Figure 17 is a graph showing the results of an experiment to show Drosophila killing by Ece1-III. The percentage of Drosophila death, 24 hours post-infection of 250µg/ml His-tagged full length Ecelp, Ecel-II(peptide 2) (Figure 2 ), and Ece1-III (peptide 3), into a cohort of 20 age-matched flies. - To investigate the role of Ecel in host cell damage, a series of C. albicans gene deletion mutants lacking ECE1, as well as revertant mutant strains were created. Specifically, C. albicans gene deletion cassettes were generated using the PCR-based method described by Dalle F et al. Cellular Microbiology 2010; 12:248-71. Primers ECE1-FG and ECE1-RG as shown below as
SEQ ID NO Candida integrating plasmid 10 or CIp10 (Murad et al. Yeast (2000) 16, 4, p325-327), yielding the ece1Δ deletion strain. For generation of the complemented strain, the ECE1 open reading frame, plus upstream and downstream intergenic regions were amplified with primers ECE1-RecF3k (SEQ ID NO 6) and ECE1-RecR (SEQ ID NO 7) and cloned into plasmid CIp10 at MluI and SalI sites, yielding plasmid CIp10-ECE1. This plasmid was transfomed into the uridine auxotrophic ece1Δ - deletion strain, yielding the ece1Δ/Δ - ECE1 complemented strain. -
- ECE1-FG
- ECE1-RG
- ECE1-RecF3k
GCACGCGTCTAAAGTGGAGTAACAAC (SEQ ID NO 6) - ECE1-RecR
GGTCGACCCCAGACGTTGGTTGC (SEQ ID NO 7) - Three strains, wild type C. albicans (wt), the ECE1 deletion mutant (ece1Δ) and the revertant mutant strain (ece1Δ/Δ - ECE1) were tested. They were applied to three independent human epithelial cell types: oral, gastrointestinal and vaginal. TR146, Caco-2 and A431 epithelial cell lines were maintained as previously described in the Dalle and Wachtler references given above. Epithelial damage assays were performed as previously described by Dalle et al. (supra.) and Wachtler et al. (2011) (supra.) with the following modifications: monolayers in 96 well plates were infected with 2 × 104 C. albicans cells; infections were performed in cell culture media without fetal bovine serum.
- After incubation for 24 hours, the damage to the cells was assessed by measuring lactate dehydrogenase (LDH) release using a conventional assay method.
- The results are shown in
Figure 1 . They show that deletion of ECE1, prevented or reduced C. albicans damage in all three cell types. As C. albicans is often found associated with the oral, gastrointestinal and urogenitary sites as a member of the natural microbiome, but can also cause infections at such sites, these data suggest that the ECE1 gene product is involved C. albicans pathogenicity. - It has been demonstrated that Ecel can be proteolytically processed by Kex2 into eight peptide fragments (O. Bader et al. BMC Microbiology 2008, 8:115).
Figure 2 illustrates the structure of Ecel and the proposed resultant peptide fragments following proteolytic processing as well as its phylogenic relationship with orthologues in C. dubliniensis and C. tropicalis (note that ECE1 orthologues are only found in these two fungal species). Each of the individual C. albicans peptides were synthesised by ProteoGenix using fmoc solid phase peptide synthesis technology. - The method of Example 1 was then repeated using a 1:1 mixture of peptides (1-7) of
Figure 2 on human TR146 oral epithelial cells at various concentrations (250µg/ml, 125µg/ml, 62.5µg/ml, 31.25µg/ml, 15.625µg/ml and 7.8µg/ml of each individual peptide within the mixture) or peptide 3 (SEQ ID NO 1) alone in the presence of the ece1Δ mutant C. albicans.Peptide 8 could not be included, as this peptide was insoluble. After incubations for 24 hours, the damage was assessed by measuring LDH release as before. The results are shown inFigure 3A . This shows that peptide 3 (designated Ece1-III in the Figure) produced similar levels of damage to the combination at a concentration of 250µg/ml. - The test was then repeated using each peptide individually without C. albicans cells. The results are shown in
Figure 3B and C . They show that whilstpeptide 3 was capable of damaging both oral epithelial and vaginal cells, the other peptides displayed essentially no cytolytic activity. Therefore,peptide 3 of processed Ecel ("Ece1-III" of SEQ ID NO 1) is sufficient to cause lysis of human epithelial cells. - In order to investigate the cytolytic activities of Ece1-III in greater detail, a haemolysis assay was carried out. Human blood was collected with the SARSTEDT blood collection system and EDTA-coated tubes, washed once with HBSS, resuspended in HBSS and stored at 4°C for up to one week for experiments. Blood was obtained from healthy human donors.
- Each individual peptide (at a final concentration of 30µg/ml) was incubated with 1 × 107 human erythrocytes in a volume of 150µl. After incubation for 1 hour at 37°C, haemolysis was assayed by measuring haemoglobin release, as indicated by absorbance at 541nm, normalised to a 100% lysis-water control.
- The results are shown in
Figure 4 . Exposure of human erythrocytes to Ece1-III, but not to the other peptides, resulted in lysis of these cells. It should be noted that, in contrast to epithelial cells, erythrocytes do not contain nuclei and cannot transcriptionally respond to stimuli. Therefore, lysis of erythrocytes by Ece1-III was due to direct cytolysis. - Many peptide toxins elicit cytotoxicity via pore formation and ion influx across membranes. Whether addition of Ece1-III to epithelial cells was able to directly induce pore formation was then tested. Oral epithelial (TR-146) monolayers were incubated with 5µg/ml Ece1-III of
SEQ ID NO 1 for 5 hours and pore formation assessed by scanning electron microscopy. The results are shown inFigure 5 where panel B shows a further magnified view of the region shown in panel A. Electron microscopy suggests that Ecel-III can directly induce pores (Figure 5A and B ), which is in agreement with the view that Ece1-III can act as a pore-forming toxin. - Since the mode of action of many peptide and pore-forming toxins is ion-dependent, Ece1-III and erythrocytes were co-incubated in the presence of increasing concentrations of the divalent cation chelator, ethylenediaminetetraacetic acid (EDTA), which restricts the bioavailability of divalent cations. After 1 hour, haemolysis was measured as described in Example 3 above. The results, shown in
Figure 6A , indicate that increasing concentrations of EDTA blocked the haemolytic activity of Ece1-III. This effect was reversed by supplementation with magnesium (Figure 6B ). Therefore, like previously described peptide toxins, the haemolytic activity of Ece1-III appears to be ion-dependent. - Pore-forming toxins are generally strong activators of inflammatory responses. Previously it has been shown that recognition of C. albicans hyphae resulted in the activation of the mitogen-activated protein kinase (MAPK) p38 signalling pathway and the c-Fos transcription factor, which in turn activates proinflammatory cytokine production (Moyes DL, et al.: Cell Host Microbe 2010, 8:225-235,). An extensive screen of >100 C. albicans mutants was carried out using protocols described in this reference and also Moyes DL, et al. PLoS ONE 2011, 6:e26580; Murciano C. et al. Infect.Immun 2011, 79:4902-4911; Moyes DL, et al. Med Microbiol Immunol 2012, 201:93-101; Moyes DL, et al. Methods MolBiol 2012, 845:345-360 and Murciano C, et al. PLoS ONE 2012, 7:e33362.
- The results demonstrated that only a strain deleted in ECE1 was unable to activate the c-Fos pathway (
Figure 7A ) or proinflammatory cytokines (Figure 7B ) from oral epithelial cells whilst still producing hyphae. Therefore, activation of epithelial immune responses via c-Fos against C. albicans is the result of the action and/or recognition of Ecel. - Having identified Ece1-III as the region of Ecel responsible for cellular lysis and the activation of immune responses, the applicants next investigated the precise functional requirements of the Ece1-III amino acid sequence (
Figure 8A ). Accordingly, individual peptide fragments corresponding to internal regions of Ece1-III were constructed (WTSA peptides 1-6 (SEQ ID NOS 8-11, 3 and 12 respectively:Figure 8B ). The sequence of each WTSA peptide was chosen to facilitate a detailed examination of each of the internal amyloidogenic regions of Ece1-III, either alone (WTSA peptides Figure 8B ). The WTSA peptides were analysed for their ability to cause epithelial cell lysis. However, none of the individual WTSA peptide fragments were observed to induce cell lysis (Figure 9 ). Notably, whenWTSA Figure 10 ). In contrast, a potent induction of all cytokines was observed following exposure to full length Ece1-III. Taken together, these data indicate that only intact, full length Ece1-III is capable of inducing cellular lysis and stimulation of the inflammatory response in epithelial cells. - The p38/c-Fos pathway is activated via the interaction of C. albicans hyphae with the surface receptor EGFR (epidermal growth factor receptor), as blocking EGFR activation also blocks c-Fos activation (
Figure 11A ). Biacore binding assays show that Ece1-III (of SEQ ID NO 1), but not other parts of the Ecel protein, directly interact with EGFR with high affinity (Figure 11B ) and that blocking EGFR abolishes the ability of Ece1-III to activate c-Fos (Figure 11C ). Furthermore, blocking EGFR also reduced/abolished activation of all three MAPK signalling pathways (p38, JNK and ERK1/2) (Fig. 12 ) This demonstrates that activation of mucosal immune responses via the p38/c-Fos pathway is the result of Ecel-III/EGFR interactions and that EGFR plays a primary role in the activation of cell signalling by Ece1-III. - In order to insert into a target membrane, a pore-forming peptide toxin must interact with components of the membrane. Because Ece1-III consists of a predicted alpha helix with a dibasic (lysine, arginine) C-terminal head, the applicants predicted that these cationic, positively charged residues may interact with negatively charged phospholipids present in target membranes. Ece1-III was used to probe a phospholipid array (PIP Strip membrane). Binding was assessed by hybridisation with anti-Ece1-III antibody, followed by detection with anti-rabbit antibody conjugated to horse radish peroxidase. The results are shown in
Figure 13 . These show that Ece1-III interacts with Phosphatidylinositol-3-phosphate, Phosphatidylinositol-4-phosphate, Phosphatidylinositol-5-phosphate, Phosphatidylinositol-3,4-phosphate, Phosphatidylinositol-3,5 -phosphate, Phosphatidylinositol-4,5-phosphate, Phosphatidylinositol-3,4,5-phosphate, Phosphatidic acid and Phosphatidylserine, with binding to Phosphatidylinositol-3-phosphate being particularly robust (Figure 13 ). Ece1-III did not interact with Lysophosphatidic acid, Lysophosphatidylcholine, Phosphatidylinositol, Phosphatidylethanolamine, Phosphatidylcholine or Sphingosine-1-phosphate. Therefore, insertion of Ece1-III into target membranes (pore formation) may be mediated by interactions with phospholipids. - Given the importance of Ece1-III in killing epithelial cells, the applicants examined whether it also plays a role in immune escape of C. albicans from macrophages. In vitro, C. albicans yeast cells are phagocytosed by macrophages, but rapidly germinate and escape the macrophage via hypha formation. To examine whether Ecel is involved in this process, wild type, ece1Δ, and ece1Δ/Δ - ECE1 cells were coincubated with macrophages and the following parameters measured: phagocytosis rates, length of hyphae, escape from macrophages, and damage of macrophages. Interestingly, ece1Δ cells were phagocytosed by macrophages at the same rate, formed hyphae within macrophages of the same length, and even escaped from macrophages at the same rates as the wild type, but were unable to damage these immune cells (
Figure 14 and15 ). These data demonstrate that C. albicans hyphae can non-lytically escape from macrophages, and indicate a specific role for Ecel in host cell damage. - The applicants also tested whether Ecel was required for mucosal pathogenciity in vivo. To test this, they utilised a murine model of oropharyngeal candidiasis. In this model, mice were first immunosuppressed with cortisone acetate prior to administration of wild-type (parental) C. albicans (BWP17), a ece1Δ null mutant and ece1Δ/Δ - ECE1 revertant strain into the oral cavity. After four days, fungal burdens, fungal invasion, tissue damage and immune cell recruitment was determined in tongue tissues. Significantly lower fungal burdens were found in mice infected with the ece1Δ null mutant as compared with the wild-type (BWP17) or the ece1Δ/Δ - ECE1 revertant strains, and in many cases the ece1Δ null mutant could not be recovered from mice (
Figure 16 A) . Histological analysis of mouse tongues in both the wild-type (BWP17) and ece1Δ/Δ - ECE1 revertant strain showed multiple foci of infection that were associated with inflammatory immune cells (neutrophils) and extensive local tissue damage (Figure 16 B-D ). In contrast, mice infected with the ece1Δ null mutant showed no evidence of any foci of invasion, tissue damage or inflammation and no evidence of C. albicans was detectable (Figure 16 E) . Therefore, Ecel is essential for successful mucosal infection, damage induction and immune activation in this model. - The applicants also determined the effect of administering full length His-tagged Ecelp and Ece1-III in a Drosophila melanogaster (fruit fly) model. All flies injected with full length His-tagged Ecelp and Ece1-III displayed signs of paralysis, with only 17.5% and 10% recovering after 24 hours, as compared with the negative control Ecel-II (peptide 2) which showed no signs of paralysis (
Figure 17 ). This indicates that Ece1-III may have a direct or indirect neurotoxic effect. - These data provide evidence that Ecel (and its active component Ece1-III) has a dual functional role, by acting both as a pore-forming toxin that damages host cells and as an activator of immune responses. Damage of host cells and uncontrolled immune activation are the hallmarks of several diseases caused by C. albicans, which can often lead to death (45- 76% mortality) during systemic infections. Therefore, neutralisation of Ece1-III will prevent not only host damage during C. albicans infections but also deleterious inflammatory responses. This indicates that Ece1-III represents a new therapeutic target to treat C. albicans infections.
-
- <110> King's College London
Leibniz Institute fur Naturstoff-Forschung und Infektionshbioligie e.v. - <120> Peptides and Binding Partners Therefor
- <130> P3010/WO
- <150>
GB1306588.3
<151> 2013-04-11 - <160> 15
- <170> BiSSAP 1.2
- <210> 1
<211> 32
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 1
- <210> 2
<211> 9
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 2
- <210> 3
<211> 10
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 3
- <210> 4
<211> 122
<212> DNA
<213> Artificial Sequence - <220>
<221> source
<222> 1..122
<223> /mol_type="unassigned DNA" /note="Primer" /organism="Artificial Sequence" - <400> 4
- <210> 5
<211> 127
<212> DNA
<213> Artificial Sequence - <220>
<221> source
<222> 1..127
<223> /mol_type="unassigned DNA" /note="Primer" /organism="Artificial Sequence" - <400> 5
- <210> 6
<211> 26
<212> PRT
<213> Artificial Sequence - <220>
<223> Primer - <400> 6
- <210> 7
<211> 23
<212> DNA
<213> Artificial Sequence - <220>
<221> source
<222> 1..23
<223> /mol_type="unassigned DNA" /note="Primer" /organism="Artificial Sequence" - <400> 7
ggtcgacccc agacgttggt tgc 23 - <210> 8
<211> 10
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 8
- <210> 9
<211> 14
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 9
- <210> 10
<211> 24
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 10
- <210> 11
<211> 14
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 11
- <210> 12
<211> 8
<212> PRT
<213> Candida albicans - <220>
<223> Peptide - <400> 12
- <210> 13
<211> 271
<212> PRT
<213> Candida albicans - <220>
<223> Ecel - <400> 13
- <210> 14
<211> 268
<212> PRT
<213> Candida dubliniensis - <220>
<223> Ecel - <400> 14
- <210> 15
<211> 282
<212> PRT
<213> Candida tropicalis - <220>
<223> Ecel - <400> 15
Claims (14)
- A peptide which is of SEQ ID NO 1
SIIGIIMGILGNIPQVIQIIMSIVKAFKGNKR (SEQ ID NO.1) or a variant thereof wherein the variant is peptide encoded by an orthologue of a gene sequence which encodes the peptide of SEQ ID NO 1 derived from an Ecel protein of a Candida species, or a peptide which is at least 87% identical to SEQ ID No 1; or a fragment of either of these of from 20 to 31 amino acids in length; or a labelled form thereof, wherein the peptide has a cell-activating, damage-inducing, immunomodulatory or immunogenic ability. - A peptide according to claim 1 which comprises at least one of SEQ ID NO.2 or SEQ ID NO 3:
IIGIIMGIL (SEQ ID NO. 2) QVIQIIMSIV (SEQ ID NO. 3). - A peptide according to claim 1 or claim 2 which is of SEQ ID NO 1.
- A peptide according to claim 1 which is a peptide encoded by an orthologue of a gene sequence from C. dubliniensis of SEQ ID NO 16
SIIGILTAILNNVPQIINVITTIIKSIITGNKR (SEQ ID NO. 16)
or from C. tropicalis of SEQ ID NO 17
ISFAGIVSSIINQLPSIIQIIGNIIKAGLVKR (SEQ ID NO. 17). - A peptide according to any one of the preceding claims which is a fragment which lacks the dibasic (KR) C-terminal head.
- A specific binding partner for a peptide according to any one of claims 1 to 4, or a labelled form thereof, wherein the specific binding partner is an antibody or a binding fragment thereof, for use in the treatment or prevention of infection by Candida species.
- A pharmaceutical composition comprising a peptide according to any one of claims 1 to 4 or a specific binding partner according to claim 6 and a pharmaceutically acceptable carrier.
- A peptide according to any one of claims 1 to 4 for use in therapy, such as for the treatment or prevention of infection by Candida albicans.
- A nucleic acid that encodes a peptide according to any one of claims 1 to 4.
- A recombinant cell that has been transformed with a nucleic acid according to claim 9.
- A method for producing a peptide to any one of claims 1 to 4, which method comprises culturing a recombinant cell according to claim 10 and recovering said peptide therefrom.
- A method for diagnosis of an infection by C. albicans, said method comprising contacting a sample which has been obtained from an individual with a peptide according to any one of claims 1 to 4, and detecting whether the sample contains moieties that interact with said peptide at a sufficient level to indicate a pathogenic invasive infection.
- A kit for diagnosing an infection by C. albicans, said kit comprising a peptide according to any one of claims 1 to 4, and means for detecting complexes formed between said peptide and a specific binding partner.
- An in vitro method for screening for compounds having anti-fungal activity, said method comprising determining whether a test compound will interact with a peptide according to any one of claims 1 to 4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1306588.3A GB201306588D0 (en) | 2013-04-11 | 2013-04-11 | Peptides and Binding Partners Therefor |
PCT/GB2014/051118 WO2014167335A1 (en) | 2013-04-11 | 2014-04-10 | Peptides and binding partners therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2984103A1 EP2984103A1 (en) | 2016-02-17 |
EP2984103B1 true EP2984103B1 (en) | 2019-06-12 |
Family
ID=48537092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14722312.7A Active EP2984103B1 (en) | 2013-04-11 | 2014-04-10 | Peptides and binding partners therefor |
Country Status (5)
Country | Link |
---|---|
US (2) | US9969796B2 (en) |
EP (1) | EP2984103B1 (en) |
CN (1) | CN105377883A (en) |
GB (1) | GB201306588D0 (en) |
WO (1) | WO2014167335A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201306588D0 (en) | 2013-04-11 | 2013-05-29 | King S College London | Peptides and Binding Partners Therefor |
WO2020130838A2 (en) * | 2018-12-21 | 2020-06-25 | Qvq Holding B.V. | Antibodies for preventing or treating candidiasis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747137B1 (en) * | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
EP1235918B1 (en) | 1999-11-29 | 2007-03-21 | Trustees of Dartmouth College | Methods for altering the expression of hyphal-specific genes |
WO2006036817A2 (en) * | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Fungal variants and uses thereof |
MX2012000018A (en) | 2009-07-03 | 2012-03-29 | Los Angeles Biomed Res Inst | Hyr1 as a target for active and passive immunization against candida. |
GB201306588D0 (en) | 2013-04-11 | 2013-05-29 | King S College London | Peptides and Binding Partners Therefor |
-
2013
- 2013-04-11 GB GBGB1306588.3A patent/GB201306588D0/en not_active Ceased
-
2014
- 2014-04-10 CN CN201480033206.2A patent/CN105377883A/en active Pending
- 2014-04-10 EP EP14722312.7A patent/EP2984103B1/en active Active
- 2014-04-10 WO PCT/GB2014/051118 patent/WO2014167335A1/en active Application Filing
- 2014-04-10 US US14/783,237 patent/US9969796B2/en active Active
-
2018
- 2018-03-23 US US15/933,660 patent/US20180215812A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US20160046699A1 (en) | 2016-02-18 |
US20180215812A1 (en) | 2018-08-02 |
WO2014167335A1 (en) | 2014-10-16 |
CN105377883A (en) | 2016-03-02 |
EP2984103A1 (en) | 2016-02-17 |
GB201306588D0 (en) | 2013-05-29 |
US9969796B2 (en) | 2018-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7241613B1 (en) | Identification of Candida cell surface proteins and their uses | |
EP2998740A1 (en) | Method for predicting clinical effect of immunotherapy | |
WO2005061532A1 (en) | Pathogenic infection detection compositions and methods | |
US10806776B2 (en) | Method of treating fungal infection | |
US20180215812A1 (en) | Peptides and binding partners therefor | |
KR20100028558A (en) | Pseudomonas aeruginosa outer membrane protein pa4710 | |
JP2000502070A (en) | Treatment and diagnosis of infections by Helicobacter pylori | |
CN101454446A (en) | Pseudomonas aeruginosa outer membrane protein PA0427 | |
CN110476065B (en) | Diagnostic method | |
US20170198021A1 (en) | Methods of treating diabetes and compositions capable of same | |
WO2007049770A1 (en) | Outer coat protein pa5158 of pseudomonas aeruginosa | |
US11655274B2 (en) | Glycosylated YghJ polypeptides from enterotoxigenic Escherichia coli (ETEC) | |
AU684009B2 (en) | Peptides for diagnostics | |
US11492391B1 (en) | Intracellular nanobody targeting T4SS effector inhibits ehrlichia infection | |
US20240192209A1 (en) | Diagnosis of bartonella using recombinant proteins | |
EP2396655B1 (en) | Device for serological investigation of yersinia infections and/or subsequent illnesses and use of proteins MyfA and PsaA of Y enterocolitica and Y. pseudotuberculosis as recombinant antigens | |
NL2023527B1 (en) | Peptides for use in the treatment of cholera | |
WO2015154783A1 (en) | Glycosylated polypeptides originating from enterotoxigenic escherichia coli (etec) | |
CN115724940A (en) | Targeted STAT3 protein Tyr705 phosphorylation peptide and application thereof | |
Emrick | Characterization of the fungicidal activity and biochemical impact of occidiofungin, a novel antifungal compound derived from Burkholderia contaminans | |
WO2012126172A1 (en) | Peptides inhibiting adhesion of aspergillus fumigatus to cornea | |
CN110958886A (en) | Plasmodium falciparum and plasmodium vivax vaccines | |
Li et al. | E03-08-0618, Revised January 8, 2004 Clustering and redistribution of late endocytic compartments in response to Helicobacter pylori vacuolating toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151023 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HUBE, BERNHARD Inventor name: NAGLIK, JULIAN Inventor name: MOYES, DAVID Inventor name: WILSON, DUNCAN Inventor name: RICHARDSON, JONATHAN Inventor name: TANG, SHIRLEY Inventor name: HOFS, SARAH |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170131 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180918 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20190307 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1142433 Country of ref document: AT Kind code of ref document: T Effective date: 20190615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014048169 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: LATSCHA SCHOELLHORN PARTNER AG, CH |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190912 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190913 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190912 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1142433 Country of ref document: AT Kind code of ref document: T Effective date: 20190612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191014 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191012 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014048169 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
26N | No opposition filed |
Effective date: 20200313 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190612 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230519 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602014048169 Country of ref document: DE Representative=s name: MAIWALD GMBH, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240422 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240411 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240418 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240417 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20240419 Year of fee payment: 11 |